Jiabin Cai

6.1k total citations · 2 hit papers
89 papers, 3.3k citations indexed

About

Jiabin Cai is a scholar working on Molecular Biology, Surgery and Cancer Research. According to data from OpenAlex, Jiabin Cai has authored 89 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 23 papers in Surgery and 21 papers in Cancer Research. Recurrent topics in Jiabin Cai's work include Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and RNA modifications and cancer (10 papers). Jiabin Cai is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (11 papers) and RNA modifications and cancer (10 papers). Jiabin Cai collaborates with scholars based in China, Ethiopia and United States. Jiabin Cai's co-authors include Ai‐Wu Ke, Jia Fan, Jia‐Cheng Lu, Pengfei Zhang, Guo‐Ming Shi, Xiaoyong Huang, Chao Gao, Xiaojun Guo, Yi-Min Zheng and Jian Zhou and has published in prestigious journals such as Journal of the American Chemical Society, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Jiabin Cai

86 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer cell-derived exosomal circUHRF1 induces natural killer cell exhaustion and may cause resistance to anti-PD1 therapy in hepatocellular carcinoma

2020 465 citations Pengfei Zhang, Chao Gao et al. profile →
Current applications and future perspective of CRISPR/Cas9 gene editing in cancer

2022 292 citations Chao Gao, Yi-Min Zheng et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jiabin Cai China	27	2.3k	1.4k	547	380	316	89	3.3k
Hongbo Zhu China	31	2.6k 1.1×	981 0.7×	1.1k 2.1×	332 0.9×	501 1.6×	95	4.3k
Mihai Gagea United States	27	1.6k 0.7×	784 0.6×	506 0.9×	363 1.0×	154 0.5×	62	2.4k
Runzhou Ni China	29	1.8k 0.8×	711 0.5×	436 0.8×	417 1.1×	238 0.8×	103	2.4k
Fei Ji China	29	2.0k 0.8×	963 0.7×	570 1.0×	157 0.4×	232 0.7×	90	3.0k
Shengyong Yin China	27	1.3k 0.5×	603 0.4×	879 1.6×	547 1.4×	240 0.8×	78	2.7k
Ruozhen Hu United States	20	2.1k 0.9×	1.1k 0.8×	1.1k 2.0×	1.2k 3.2×	304 1.0×	26	3.4k
Jiansong Ji China	26	904 0.4×	548 0.4×	557 1.0×	389 1.0×	348 1.1×	82	2.2k
Kris Ylaya United States	25	1.0k 0.4×	527 0.4×	816 1.5×	444 1.2×	362 1.1×	45	2.0k
Julia Schüler Germany	20	1.8k 0.8×	1.1k 0.8×	1.4k 2.6×	294 0.8×	296 0.9×	78	3.1k
Naoya Sakamoto Japan	32	1.8k 0.8×	1.0k 0.8×	1.1k 2.0×	250 0.7×	624 2.0×	172	3.2k

Countries citing papers authored by Jiabin Cai

Since Specialization

Citations

This map shows the geographic impact of Jiabin Cai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiabin Cai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiabin Cai more than expected).

Fields of papers citing papers by Jiabin Cai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiabin Cai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiabin Cai. The network helps show where Jiabin Cai may publish in the future.

Co-authorship network of co-authors of Jiabin Cai

This figure shows the co-authorship network connecting the top 25 collaborators of Jiabin Cai. A scholar is included among the top collaborators of Jiabin Cai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiabin Cai. Jiabin Cai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zheng, Yi-Min, Chao Gao, Wenxin Xu, et al.. (2025). The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC. Hepatology. 83(4). 771–788.

Shi, Hui, Rong Gao, Wei Zhang, et al.. (2025). Liver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma. Nature Communications. 16(1). 11034–11034.

Xu, Ru, Jian‐Guo Dai, Raymond S. Tu, et al.. (2025). Dihydrotanshinone I Targets PGAM1 to Induce SYVN1 ‐Mediated Ubiquitination and Suppress Glycolysis in Hepatocellular Carcinoma. Phytotherapy Research. 39(8). 3762–3783. 1 indexed citations

Wang, Rui, Xiaoshuang Shi, Yidi Chen, et al.. (2024). Cross-attention guided loss-based deep dual-branch fusion network for liver tumor classification. Information Fusion. 114. 102713–102713. 5 indexed citations

He, Min, Yuwei Wang, Jiabin Cai, et al.. (2024). Robot-assisted resection of renal tumor in children and comparison with laparoscopic surgery. BMC Surgery. 24(1). 325–325. 1 indexed citations

Zheng, Yi-Min, Yining Wang, Lu Zhou, et al.. (2023). PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy. Advanced Science. 10(29). e2301928–e2301928. 54 indexed citations

Wang, Liyang, Danjun Song, Chengquan Li, et al.. (2023). Data-Driven Assisted Decision Making for Surgical Procedure of Hepatocellular Carcinoma Resection and Prognostic Prediction: Development and Validation of Machine Learning Models. Cancers. 15(6). 1784–1784. 7 indexed citations

Guo, Xiaojun, Xiaoyong Huang, Xuan Yang, et al.. (2023). Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis. Cell Death and Disease. 14(2). 79–79. 14 indexed citations

Cai, Jiabin, et al.. (2023). Single-Incision Laparoscopic Percutaneous Extraperitoneal Surgery for the Treatment of Incarcerated Indirect Inguinal Hernia in Children. Journal of Laparoendoscopic & Advanced Surgical Techniques. 34(1). 88–91.

10.

Cai, Jiabin, Xuan Wu, Jin‐Yan Wang, et al.. (2023). Perioperative complication incidence and risk factors for retroperitoneal neuroblastoma in children: analysis of 571 patients. World Journal of Pediatrics. 20(3). 250–258. 2 indexed citations

11.

Cai, Jiabin, Wenjing Yang, Baishen Pan, et al.. (2022). Combining γ‐GT, PIVKA‐II, and AFP to predict long‐term prognosis in patients with hepatocellular carcinoma after hepatectomy. Clinical and Experimental Pharmacology and Physiology. 50(4). 287–297. 3 indexed citations

12.

Yu, Mincheng, Guangyu Ding, Peng Ma, et al.. (2021). CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression. Carcinogenesis. 42(10). 1293–1303. 22 indexed citations

13.

He, Min, Jiabin Cai, Kun Zhu, et al.. (2021). Renal cell carcinoma in children and adolescents. Medicine. 100(2). e23717–e23717. 7 indexed citations

14.

Cai, Jiabin, Jinhu Wang, Min He, et al.. (2021). A novel WT1 gene mutation in a chinese girl with denys‐drash syndrome. Journal of Clinical Laboratory Analysis. 35(5). 1 indexed citations

15.

Li, Shuangqi, Feizhen Wu, Jiabin Cai, et al.. (2020). TET 2 promotes anti‐tumor immunity by governing G‐ MDSC s and CD 8 ⁺ T‐cell numbers. EMBO Reports. 21(10). e49425–e49425. 34 indexed citations

16.

Li, Xiao‐Long, Xiao‐Dong Zhu, Xuefeng Liu, et al.. (2020). A prospective study of the effect of terlipressin on portal vein pressure and clinical outcomes after hepatectomy: A pilot study. Surgery. 167(6). 926–932. 8 indexed citations

17.

Zhou, Qiang, Hao Cai, Minghao Xu, et al.. (2020). Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?. Hepatobiliary & pancreatic diseases international. 20(1). 13–20. 11 indexed citations

18.

Peng, Rui, Pengfei Zhang, Xuan Yang, et al.. (2019). Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research. 38(1). 113–113. 45 indexed citations

19.

Dong, Zhao‐Ru, Dong Sun, Guo‐Ming Shi, et al.. (2017). Preoperative Albumin-Bilirubin Score for Postoperative Solitary Hepatocellular Carcinoma within the Milan Criteria and Child-Pugh A Cirrhosis. Journal of Cancer. 8(18). 3862–3867. 24 indexed citations

20.

Zheng, Liduan, Qiangsong Tong, Jun He, et al.. (2008). Enhanced Expression of Resistin-like Molecule Beta in Human Colon Cancer and Its Clinical Significance. Digestive Diseases and Sciences. 54(2). 274–281. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact